Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1)

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 3, 2009, Pages 155-160

  Nguyen, Su Duy ^a   Hung, Nguyen Dang ^b   Cheon Ho, Park ^b   Ree, Kim Mee ^b   Dai Eun, Sok ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Chungnam National University   (South Korea)

Author keywords

Antioxidant; Arylesterase; Lactonase; Oxidative inactivation; Paraoxonase; Reactive oxygen specie

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; ASCORBIC ACID; CATALASE; CUPRIC ION; FERROUS ION; GLUCONOLACTONASE; HYDROXYL RADICAL; OLEIC ACID; PHOSPHATIDYLCHOLINE;

ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ARYLDIALKYLPHOSPHATASE; ASCORBIC ACID; CATALYSIS; COPPER; ENZYME INHIBITORS; HUMANS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION;

EID: 60249083427     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2008.11.009     Document Type: Article

References (41)

1. La Du B.N. Structural and functional diversity of paraoxonases. Nat. Med. 2 (1996) 1186-1187
2. Draganov D.I., and La Du B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 78-88
3. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
4. Costa L.G., Cole T.B., Jarvik G.P., and Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu. Rev. Med. 54 (2003) 371-392
5. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
6. Rozenberg O., Rosenblat M., Coleman R., Shih D.M., and Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic. Biol. Med. 34 (2003) 774-784
7. Mackness B., Quarck R., Verreth W., Mackness M., and Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1545-1550
8. Rozenberg O., Shih D.M., and Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181 (2005) 9-18
9. Mackness B., Hine D., Liu Y., Mastorikou M., and Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318 (2004) 680-683
10. Rosenblat M., Vaya J., Shih D., and Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179 (2005) 69-77
11. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., and La Du B.N. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 (2000) 1335-1342
12. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., and La Du B.N. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem. 275 (2000) 33435-33442
13. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
14. Teiber J.F., Draganov D.I., and La Du B.N. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66 (2003) 887-896
15. Aharoni A., Gaidukov L., Yagur S., Toker L., Silman I., and Tawfik D.S. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc. Natl. Acad. Sci. U. S. A 101 (2004) 482-487
16. Adams T.B., Greer D.B., Doull J., Munro I.C., Newberne P., Portoghese P.S., Smith R.L., Wagner B.M., Weil C.S., Woods L.A., and Ford R.A. The FEMA GRAS assessment of lactones used as a flavour ingredients. The Flavor and Extract Manufacturers' Association. Generally recognized as safe. Food Chem. Toxicol. 36 (1998) 249-278
17. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46 (2005) 1239-1247
18. Nguyen S.D., and Sok D.E. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic. Res. 37 (2003) 1319-1330
19. Nguyen S.D., Kim J.R., Kim M.R., Jung T.S., and Soka D.E. Copper ions and hypochlorite are mainly responsible for oxidative inactivation of paraoxon-hydrolyzing activity in human high density lipoprotein. Toxicol. Lett. 147 (2004) 201-208
20. Rodrigo L., Mackness B., Durrington P.N., Hernandez A., and Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem. J. 354 (2001) 1-7
21. Nguyen S.D., and Sok D.E. Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem. J. 375 (2003) 275-285
22. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
23. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991) 100-106
24. Khersonsky O., and Tawfik D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. ChemBioChem 7 (2006) 49-53
25. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., and Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281 (2006) 7657-7665
26. Nguyen S.D., Jeong T.S., Kim M.R., and Sok D.E. Broad-spectrum antioxidant peptides derived from His residue-containing sequences present in human paraoxonase 1. Free Radic. Res. 40 (2006) 349-358
27. Kuo C.L., and La Du B.N. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab. Dispos. 26 (1998) 653-660
28. Bray T.M., and Bettger W.J. The physiological role of zinc as an antioxidant. Free Radic. Biol. Med. 8 (1990) 281-291
29. Gaidukov L., and Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 44 (2005) 11843-11854
30. Kleinschmidt J.H., and Tamm L.K. Structural transitions in short-chain lipid assemblies studied by (31)P-NMR spectroscopy. Biophys. J. 83 (2002) 994-1003
31. Sorenson R.C., Primo-Parmo S.L., Kuo C.L., Adkins S., Lockridge O., and La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. U. S. A 92 (1995) 7187-7191
32. Biggadike K., Angell R.M., Burgess C.M., Farrell R.M., Hancock A.P., Harker A.J., Irving W.R., Ioannou C., Procopiou P.A., Shaw R.E., Solanke Y.E., Singh O.M., Snowden M.A., Stubbs R.J., Walton S., and Weston H.E. Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. J. Med. Chem. 43 (2000) 19-21
33. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Med. 37 (2004) 1304-1316
34. Rozenberg O., Shiner M., Aviram M., and Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic. Biol. Med. 44 (2008) 1951-1959
35. Stadtman E.R., and Oliver C.N. Metal-catalyzed oxidation of proteins. Physiological consequences. J. Biol. Chem. 266 (1991) 2005-2008
36. Rosenblat M., Karry R., and Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 187 (2006) 74-81
37. Kabaroglu C., Mutaf I., Boydak B., Ozmen D., Habif S., Erdener D., Parildar Z., and Bayindir O. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol. 59 (2004) 606-611
38. Ferre N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., Coll B., Tous M., and Joven J. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J. Hepatol. 45 (2006) 51-59
39. Kotur-Stevuljevic J., Spasic S., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V., Stefanovic A., Vujovic A., Memon L., and Kalimanovska-Ostric D. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin. Biochem. 41 (2008) 1067-1073
40. Lakshman M.R., Gottipati C.S., Narasimhan S.J., Munoz J., Marmillot P., and Nylen E.S. Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus. Metabolism 55 (2006) 1201-1206
41. Pasca S.P., Nemes B., Vlase L., Gagyi C.E., Dronca E., Miu A.C., and Dronca M. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 78 (2006) 2244-2248